Tower Research Capital LLC TRC Has $59,000 Position in RxSight, Inc. (NASDAQ:RXST)

Tower Research Capital LLC TRC cut its position in shares of RxSight, Inc. (NASDAQ:RXST) by 51.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,474 shares of the company’s stock after selling 1,572 shares during the period. Tower Research Capital LLC TRC’s holdings in RxSight were worth $59,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. RiverPark Advisors LLC increased its position in RxSight by 70.0% during the fourth quarter. RiverPark Advisors LLC now owns 668 shares of the company’s stock worth $27,000 after buying an additional 275 shares during the last quarter. BluePath Capital Management LLC acquired a new position in shares of RxSight during the 3rd quarter worth approximately $32,000. Amalgamated Bank raised its stake in RxSight by 7.7% in the 4th quarter. Amalgamated Bank now owns 4,148 shares of the company’s stock valued at $167,000 after acquiring an additional 298 shares during the period. Clear Rock Advisors LLC acquired a new stake in RxSight during the 4th quarter valued at $172,000. Finally, Clarus Group Inc. bought a new position in RxSight during the fourth quarter worth $202,000. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at RxSight

In other RxSight news, Director Bakker Juliet Tammenoms purchased 4,000 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were bought at an average price of $50.38 per share, for a total transaction of $201,520.00. Following the purchase, the director now owns 25,840 shares in the company, valued at approximately $1,301,819.20. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other RxSight news, Director William J. Phd Link sold 28,250 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $49.67, for a total transaction of $1,403,177.50. Following the sale, the director now owns 24,248 shares of the company’s stock, valued at $1,204,398.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bakker Juliet Tammenoms purchased 4,000 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was purchased at an average price of $50.38 per share, with a total value of $201,520.00. Following the completion of the purchase, the director now directly owns 25,840 shares in the company, valued at approximately $1,301,819.20. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 94,869 shares of company stock valued at $4,771,244. Company insiders own 21.13% of the company’s stock.

Analyst Upgrades and Downgrades

RXST has been the subject of a number of research reports. Oppenheimer raised their target price on shares of RxSight from $54.00 to $61.00 and gave the stock an “outperform” rating in a research note on Thursday, February 29th. Stifel Nicolaus raised their price objective on shares of RxSight from $54.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, February 29th. JPMorgan Chase & Co. boosted their price objective on RxSight from $40.00 to $62.00 and gave the stock an “overweight” rating in a report on Thursday, February 29th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $64.00 target price on shares of RxSight in a research note on Thursday, April 11th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $49.63.

RxSight Price Performance

RxSight stock traded up $0.49 during mid-day trading on Monday, reaching $53.26. 423,365 shares of the company were exchanged, compared to its average volume of 427,085. The company has a fifty day simple moving average of $52.55 and a 200-day simple moving average of $42.14. The firm has a market cap of $1.98 billion, a PE ratio of -37.24 and a beta of 1.22. RxSight, Inc. has a 12 month low of $17.59 and a 12 month high of $58.21.

RxSight (NASDAQ:RXST) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.10. RxSight had a negative return on equity of 31.16% and a negative net margin of 54.57%. The business had revenue of $28.58 million during the quarter, compared to the consensus estimate of $28.60 million. Sell-side analysts anticipate that RxSight, Inc. will post -0.94 earnings per share for the current year.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.